FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:526-528 August 5, 2004 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Juurlink, D. N. PubMed Citation

The application of evidence based on the results of clinical trials is a key aim of modern medical practice. Viewed from that perspective, the findings of Juurlink and colleagues in this issue of the Journal (pages 543–551) could be considered encouraging. The Randomized Aldactone Evaluation Study (RALES) showed that, when added to standard treatment (including an angiotensin-converting–enzyme [ACE] inhibitor), a low dose of the aldosterone antagonist spironolactone reduced the risk of death by 30 percent over an average follow-up period of two years among carefully selected patients with current or recent heart failure of New York Heart Association (NYHA) functional . . . [Full Text of this Article]

Source Information

From the Department of Cardiology, Western Infirmary, Glasgow, Scotland, United Kingdom.

This article has been cited by other articles:

• Desai, A. (2008). Hyperkalemia Associated With Inhibitors of the Renin-Angiotensin-Aldosterone System: Balancing Risk and Benefit. Circulation 118: 1609-1611 [Full Text]  
• Desai, A. S., Swedberg, K., McMurray, J. J.V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., Michelson, E. L., Pfeffer, M. A., on behalf of the CHARM Program Investigators, (2007). Incidence and Predictors of Hyperkalemia in Patients With Heart Failure: An Analysis of the CHARM Program. J Am Coll Cardiol 50: 1959-1966 [Abstract] [Full Text]  
• Martin, U., Coleman, J. J (2006). Monitoring renal function in hypertension.. BMJ 333: 896-899 [Full Text]  
• Koch, E., Otarola, A., Kirschbaum, A. (2005). A landmark for popperian epidemiology: refutation of the randomised Aldactone evaluation study. J. Epidemiol. Community Health 59: 1000-1006 [Abstract] [Full Text]  
• McMurray, J., Cohen-Solal, A., Dietz, R., Eichhorn, E., Erhardt, L., Hobbs, F.D. R., Krum, H., Maggioni, A., McKelvie, R. S., Pina, I. L., Soler-Soler, J., Swedberg, K. (2005). Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. Eur J Heart Fail 7: 710-721 [Abstract] [Full Text]  
• McDonald, K. (2005). Current guidelines in the management of chronic heart failure: Practical issues in their application to the community population. Eur J Heart Fail 7: 317-321 [Full Text]  
• Steinberg, E. P., Luce, B. R. (2005). Evidence Based? Caveat Emptor!. Health Aff (Millwood) 24: 80-92 [Abstract] [Full Text]  
• (2004). Spironolactone Use in Practice: Risk for Hyperkalemia?. Journal Watch Cardiology 2004: 4-4 [Full Text]  
• Opie, L. H. (2004). Cellular Basis for Therapeutic Choices in Heart Failure. Circulation 110: 2559-2561 [Full Text]  
• (2004). Spironolactone Use in Practice: Risk for Hyperkalemia?. Journal Watch Cardiology 2004: 1-1 [Full Text]